[Click eStock] "SeeusTech, an Undervalued AI Medical Device Company"

Hanyang Securities analyzed on the 12th that Seeas Technology is an undervalued artificial intelligence (AI) medical device company. No investment opinion or target price was provided.

The core business of Seeas Technology is supplying hospitals with the ‘real-time inpatient monitoring system (thynC).’ This system attaches a small wireless device to the body of hospitalized patients and monitors their vital signs (electrocardiogram, blood pressure, oxygen saturation, etc.) 24 hours a day.

Byungyong Oh, a researcher at Hanyang Securities, explained, "'thynC' has the advantage of providing many more services to patients beyond cardiac arrest prediction and can receive additional fees. It enables real-time prediction and eliminates the need for nurses to manually record data. In September this year, a paper on the accuracy of ‘thynC’ in predicting cardiac arrest is also scheduled to be published."

He added, "Seeas Technology’s arrhythmia early diagnosis (long-term continuous electrocardiogram monitoring) product ‘mobiCARE’ is also promising. Arrhythmia is one of the most common heart diseases along with angina and myocardial infarction, and early diagnosis and management are important, but it is still not well known in Korea."

He continued, "‘mobiCARE’ is a lightweight detachable patch-type product that uses AI to generate interpretation reports. With ‘mobiCARE,’ arrhythmia testing can be easily conducted even at small local clinics. It is expected that arrhythmia testing will gradually become more widespread domestically, and significant benefits can be anticipated," he emphasized.

He said, "Considering Vuno’s market capitalization (KRW 441 billion), Seeas Technology’s (KRW 168.7 billion) investment appeal stands out. It is a highly undervalued AI medical device company."

This content was produced with the assistance of AI translation services.